Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 326

1.

Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.

Herman SE, Gordon AL, Hertlein E, Ramanunni A, Zhang X, Jaglowski S, Flynn J, Jones J, Blum KA, Buggy JJ, Hamdy A, Johnson AJ, Byrd JC.

Blood. 2011 Jun 9;117(23):6287-96. doi: 10.1182/blood-2011-01-328484. Epub 2011 Mar 21.

PMID:
21422473
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Dasatinib inhibits B cell receptor signalling in chronic lymphocytic leukaemia but novel combination approaches are required to overcome additional pro-survival microenvironmental signals.

McCaig AM, Cosimo E, Leach MT, Michie AM.

Br J Haematol. 2011 Apr;153(2):199-211. doi: 10.1111/j.1365-2141.2010.08507.x. Epub 2011 Feb 24.

PMID:
21352196
[PubMed - indexed for MEDLINE]
3.

The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo.

Ponader S, Chen SS, Buggy JJ, Balakrishnan K, Gandhi V, Wierda WG, Keating MJ, O'Brien S, Chiorazzi N, Burger JA.

Blood. 2012 Feb 2;119(5):1182-9. doi: 10.1182/blood-2011-10-386417. Epub 2011 Dec 16.

PMID:
22180443
[PubMed - indexed for MEDLINE]
Free Article
4.

The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia.

de Rooij MF, Kuil A, Geest CR, Eldering E, Chang BY, Buggy JJ, Pals ST, Spaargaren M.

Blood. 2012 Mar 15;119(11):2590-4. doi: 10.1182/blood-2011-11-390989. Epub 2012 Jan 25.

PMID:
22279054
[PubMed - indexed for MEDLINE]
Free Article
5.

Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL).

Woyach JA, Bojnik E, Ruppert AS, Stefanovski MR, Goettl VM, Smucker KA, Smith LL, Dubovsky JA, Towns WH, MacMurray J, Harrington BK, Davis ME, Gobessi S, Laurenti L, Chang BY, Buggy JJ, Efremov DG, Byrd JC, Johnson AJ.

Blood. 2014 Feb 20;123(8):1207-13. doi: 10.1182/blood-2013-07-515361. Epub 2013 Dec 5.

PMID:
24311722
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

The Akt/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells.

Longo PG, Laurenti L, Gobessi S, Sica S, Leone G, Efremov DG.

Blood. 2008 Jan 15;111(2):846-55. Epub 2007 Oct 10.

PMID:
17928528
[PubMed - indexed for MEDLINE]
Free Article
7.

IPI-145 antagonizes intrinsic and extrinsic survival signals in chronic lymphocytic leukemia cells.

Dong S, Guinn D, Dubovsky JA, Zhong Y, Lehman A, Kutok J, Woyach JA, Byrd JC, Johnson AJ.

Blood. 2014 Dec 4;124(24):3583-6. doi: 10.1182/blood-2014-07-587279. Epub 2014 Sep 25.

PMID:
25258342
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy.

Honigberg LA, Smith AM, Sirisawad M, Verner E, Loury D, Chang B, Li S, Pan Z, Thamm DH, Miller RA, Buggy JJ.

Proc Natl Acad Sci U S A. 2010 Jul 20;107(29):13075-80. doi: 10.1073/pnas.1004594107. Epub 2010 Jul 6.

PMID:
20615965
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

The bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) blocks hairy cell leukaemia survival, proliferation and B cell receptor signalling: a new therapeutic approach.

Sivina M, Kreitman RJ, Arons E, Ravandi F, Burger JA.

Br J Haematol. 2014 Jul;166(2):177-88. doi: 10.1111/bjh.12867. Epub 2014 Apr 2.

PMID:
24697238
[PubMed - indexed for MEDLINE]
10.

BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity.

Cheng S, Ma J, Guo A, Lu P, Leonard JP, Coleman M, Liu M, Buggy JJ, Furman RR, Wang YL.

Leukemia. 2014 Mar;28(3):649-57. doi: 10.1038/leu.2013.358. Epub 2013 Nov 25.

PMID:
24270740
[PubMed - indexed for MEDLINE]
11.

Identification of Bruton's tyrosine kinase as a therapeutic target in acute myeloid leukemia.

Rushworth SA, Murray MY, Zaitseva L, Bowles KM, MacEwan DJ.

Blood. 2014 Feb 20;123(8):1229-38. doi: 10.1182/blood-2013-06-511154. Epub 2013 Dec 4.

PMID:
24307721
[PubMed - indexed for MEDLINE]
Free Article
12.

Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia.

Wiestner A.

Hematology Am Soc Hematol Educ Program. 2012;2012:88-96. doi: 10.1182/asheducation-2012.1.88. Review. Erratum in: Hematology Am Soc Hematol Educ Program. 2013;2013:692.

PMID:
23233565
[PubMed - indexed for MEDLINE]
Free Article
13.

B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406.

Quiroga MP, Balakrishnan K, Kurtova AV, Sivina M, Keating MJ, Wierda WG, Gandhi V, Burger JA.

Blood. 2009 Jul 30;114(5):1029-37. doi: 10.1182/blood-2009-03-212837. Epub 2009 Jun 2.

PMID:
19491390
[PubMed - indexed for MEDLINE]
Free Article
14.

Targeted therapy in chronic lymphocytic leukemia: past, present, and future.

Danilov AV.

Clin Ther. 2013 Sep;35(9):1258-70. doi: 10.1016/j.clinthera.2013.08.004. Review.

PMID:
24054703
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Sustained signaling through the B-cell receptor induces Mcl-1 and promotes survival of chronic lymphocytic leukemia B cells.

Petlickovski A, Laurenti L, Li X, Marietti S, Chiusolo P, Sica S, Leone G, Efremov DG.

Blood. 2005 Jun 15;105(12):4820-7. Epub 2005 Feb 22.

PMID:
15728130
[PubMed - indexed for MEDLINE]
Free Article
16.

Ibrutinib inhibits BCR and NF-κB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL.

Herman SE, Mustafa RZ, Gyamfi JA, Pittaluga S, Chang S, Chang B, Farooqui M, Wiestner A.

Blood. 2014 May 22;123(21):3286-95. doi: 10.1182/blood-2014-02-548610. Epub 2014 Mar 21.

PMID:
24659631
[PubMed - indexed for MEDLINE]
17.

Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migration.

Hoellenriegel J, Coffey GP, Sinha U, Pandey A, Sivina M, Ferrajoli A, Ravandi F, Wierda WG, O'Brien S, Keating MJ, Burger JA.

Leukemia. 2012 Jul;26(7):1576-83. doi: 10.1038/leu.2012.24. Epub 2012 Feb 7.

PMID:
22362000
[PubMed - indexed for MEDLINE]
18.

Inhibition of NF-κB-mediated signaling by the cyclin-dependent kinase inhibitor CR8 overcomes prosurvival stimuli to induce apoptosis in chronic lymphocytic leukemia cells.

Cosimo E, McCaig AM, Carter-Brzezinski LJ, Wheadon H, Leach MT, Le Ster K, Berthou C, Durieu E, Oumata N, Galons H, Meijer L, Michie AM.

Clin Cancer Res. 2013 May 1;19(9):2393-405. doi: 10.1158/1078-0432.CCR-12-2170. Epub 2013 Mar 26.

PMID:
23532892
[PubMed - indexed for MEDLINE]
Free Article
19.

BCR signaling in chronic lymphocytic leukemia and related inhibitors currently in clinical studies.

Robak T, Robak P.

Int Rev Immunol. 2013 Aug;32(4):358-76. doi: 10.3109/08830185.2013.786711. Epub 2013 Apr 25. Review.

PMID:
23617253
[PubMed - indexed for MEDLINE]
20.

Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway.

Lapalombella R, Andritsos L, Liu Q, May SE, Browning R, Pham LV, Blum KA, Blum W, Ramanunni A, Raymond CA, Smith LL, Lehman A, Mo X, Jarjoura D, Chen CS, Ford R Jr, Rader C, Muthusamy N, Johnson AJ, Byrd JC.

Blood. 2010 Apr 1;115(13):2619-29. doi: 10.1182/blood-2009-09-242438. Epub 2009 Nov 24.

PMID:
19965642
[PubMed - indexed for MEDLINE]
Free PMC Article
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk